Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
-
REGULATORY Commodity Prices Are Rising, That’s Why Full Drug Re-Pricing Needed in 2023: MOF Official
October 25, 2022
-
REGULATORY Moderna’s BA.4/5 COVID Jab Up for PAFSC Review on Oct. 31
October 25, 2022
-
BUSINESS Genmab to Branch Out into 2nd Disease Area beyond Cancer, Specifics to Be Unveiled Next Year: CEO
October 24, 2022
-
ORGANIZATION Over 80% of Wholesaler Reps Say Shipment Adjustments Take Up Most of Their Time: Survey
October 21, 2022
-
REGULATORY With Shortened Interval, Omicron Booster Likely to Cover 18 Million More People by Month-End
October 21, 2022
-
BUSINESS Kyowa Kirin Assigns Bone Metabolism Specialists to Promote Crysvita in Japan
October 20, 2022
-
BUSINESS Sumitomo Aiming to Take the Lead in Developing Universal Flu Vaccines
October 19, 2022
-
BUSINESS Bayer to Distribute Xarelto Tablets 2.5 mg via Single Wholesaler
October 18, 2022
-
REGULATORY Health Ministry Research Team to Vet Recall Rules to Address Supply Disruptions
October 17, 2022
-
BUSINESS Fujifilm Ditches Avigan COVID-19 Program, Pulls Submission in Japan
October 17, 2022
-
BUSINESS Fertility Drugs Face Supply Woes as Demand Spikes on Health Coverage
October 14, 2022
-
REGULATORY Govt Eyes Designation of Cefazolin, Other Antibiotics as Key Resources
October 14, 2022
-
REGULATORY MHLW Expert Panel Sorts Out Discussion Points for Full Debate; Focus on Innovation, Stable Supply, and Margins
October 13, 2022
-
ACADEMIA Japan Expert Sees Lecanemab Initially Treating Only a Few Tens of Thousands of Patients with Immature Care Setup
October 12, 2022
-
BUSINESS Kyushu Univ. Spinoff Aims to File NK-Like Cells in 2025, Eyes Combo with Checkpoint Drugs
October 11, 2022
-
REGULATORY Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
-
REGULATORY MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
-
ORGANIZATION EFPIA Chief Prods Japan on Mutual Trial Data Recognition, Cooperation to Boost Attractiveness to Rival US, China
October 7, 2022
-
REGULATORY Chuikyo Kicks Off Debate on FY2023 Off-Year Drug Price Revision
October 6, 2022
ページ
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…